Evelina Vågesjö CEO 1

Tue, May 03, 2022 08:00 CET

Medium resolution

Original resolution

Subscribe

Related Releases

Ilya Pharma receives Rare Pediatric Disease Designation from the U.S. FDA for emilimogene sigulactibac for the treatment of skin wounds in SAVI patients Wed, Sep 11, 2024 14:57 CET

Ilya Pharma extends global patent coverage for ILP100 for the treatment of diseases of skin and mucosa in humans and animals Mon, May 23, 2022 09:50 CET

Ilya Pharma announces FDA clearance of IND for first-in-class ILP100-Topical immunotherapy treatment of surgical wounds in patients with prediabetes, diabetes and obesity Wed, May 04, 2022 08:30 CET